A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

Inclusion Criteria:

• Male

• Age 18-64 years (both inclusive) at the time of signing the informed consent.

• Body weight greater than or equal to (≥) 45 kilograms (kgs).

• Diagnosis of congenital haemophilia A with factor VIII (FVIII) activity less than orequal to (≤) 15 percentage (%) with or without FVIII inhibitors, based on medicalrecords.

Exclusion Criteria:

• Current or prior exposure to any prophylactic treatment for haemophilia A within 5half-lives of the medicinal product by the time of screening.

• Body mass index ≥30.0 kilogram per square meter (kg/m^2).

• Increased risk of thrombosis, e.g. known history of personal or first-degreerelative(s) with unprovoked deep vein thrombosis.

• Any clinical signs or established diagnosis of venous or arterial thromboembolicdisease.

• Any known coagulation disorders other than haemophilia A.

• Ongoing or planned immune tolerance induction therapy.

• Presence of clinically significant gastrointestinal disorders potentially affectingabsorption of drugs and/or nutrients, as judged by the investigator.